Clinical Trial

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2024 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-24.
Status change: Not Yet Recruiting → Recruiting 2024-02-04
Trial Details
NCT Number NCT05515315
Lead Sponsor Fuzhou General Hospital
Conditions Immunotherapy Esophagus Cancer
Enrollment 93 participants
Start Date 2022-05-31
Primary Completion 2025-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-07